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Obesity and overeating are among the most prevalent health concerns worldwide and individuals are increasingly using
performance and image-enhancing drugs (PIEDs) as an easy and fast way to control their weight. Among these, herbal weight-
loss products (HWLPs) often attract users due to their health claims, assumed safety, easy availability, affordable price, extensive
marketing, and the perceived lack of need for professional oversight. Reports suggest that certain HWLPs may lead to onset or
exacerbation of psychiatric disturbances. Here we review the available evidence on psychiatric adverse effects of HWLPs due to
their intrinsic toxicity and potential for interaction with psychiatric medications.
1. Introduction
Novel Psychoactive Substances (NPSs) comprise an ever-
increasing number of chemical, pharmaceutical, and herbal
drugs that are often advertised as “legal” and “safer” alterna-
tives to International Controlled Drugs (ICDs) [1, 2]. While
the use of ICDs seems to have stabilized over the past decades,
the market of NPSs has significantly grown, representing
an unprecedented challenge in the field of global health
frommedical, social, cultural, legal, and political perspectives
[1–11]. Among NPSs, a rapid spread of substances known
as “performance and image-enhancing drugs” (PIEDs) or
“lifestyle drugs” has been recorded [12, 13]. The term PIED
is an umbrella term used to describe a variety of substances
taken to enhance human abilities [14]. More specifically,
PIEDs include a wide range of substances able to modify (i)
muscles’ structure and function; (ii) weight, skin coloration,
hairs, aging processes, and body-image in general; (iii) sexual
behaviours; (iv) cognitive functioning; and (v) mood and
social behaviours [12–14].
Obesity and overeating are becoming one of the most
prevalent health concerns among all populations and age
groups worldwide, resulting in a significant increase in
mortality and morbidity [15, 16]. Though diet, exercise, and
healthy lifestyle are themainstays of obesity management [15,
16], the use of PIEDs is increasing as it is viewed as an easier
alternative to controlling weight [17–20]. In addition, the use
of PIEDs is also increasing in nonobese and nonovereating
populations [12]. The cause of this is most likely modern
society’s high focus on physical appearance, often prompting
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individuals to attempt to achieve unrealistic standards of
thinness [12, 21].
Among the different PIEDs, herbal weight-loss products
(HWLPs) often attract users due to their health claims,
assumed safety, easy availability from specialised shops and
the Internet, affordable price, extensive marketing, and the
perceived lack of need for professional oversight [17–20].
Certain HWLPs may have a significant antiobesity effect
[22], with some studies reporting potential somatic adverse
effects associated with their use [18, 19, 23]. Associations
between the use of HWLPs and onset or exacerbation of
psychiatric symptoms, includingmood disturbances, anxiety,
psychosis, addiction, and delirium have also been reported
(reviewed below). There are two main mechanisms through
whichHWLPsmayhave detrimental effects onmental health:
(i) intrinsic toxicity of the herbs and/or (ii) interactions
between herbs and psychiatricmedications [18].However, the
relationship between HWLPs and psychiatric disturbances
has been relatively unstudied so far, and there is a lack of
structured and consistent research on the topic.
The information provided in the studies reporting theo-
retical associations between HWLPs and psychiatric symp-
toms is often (i) based on single-case reports and (ii) insuf-
ficient for making reliable inferences about causality. There-
fore, rather than drawing conclusions, the purpose of this
review is to aggregate and report available data, to heighten
awareness of the possible relationship between HWLPs and
adverse psychiatric effects, and to encourage future studies
to include mental health measures in relation to this rapidly
growing pattern of substance use.
2. Methods
In the following sections, we review the evidence of HWLPs
adverse effects relevant to psychiatric conditions. In Section 3
we review the evidence of adverse psychiatric effects of
HWLPs that are attributable to the intrinsic toxicity of the
herbs; in Section 4 we review the evidence of interactions
between HWLPs and psychiatric medications. Our review
strategy started with MedLine searches to identify herbal
products with weight-loss properties. We then performed
more specific MedLine searches to explore adverse psy-
chiatric effects (on humans) and interactions with psychi-
atric medications for each herbal product with documented
weight-loss properties.
3. Intrinsic Toxicity of Weight-Loss
Herbal Products
3.1. Panax ginseng. Panax ginseng (ginseng) is a perennial
herb native to Korea and China, the root of which has been
traditionally used as an “adaptogenic” substance, that is, a
compound meant to nonspecifically contribute to the sta-
bilization of physiological processes and the promotion of
health and homeostasis [24]. It is often used for weight-
loss purposes, as it has been suggested to improve glucose
tolerance, reduce LDL plasma levels, and contribute to global
inhibition of body weight gain [19, 25]. There is evidence of
ginseng modulatory activity on the noradrenergic, dopamin-
ergic, serotoninergic, cholinergic, and endorphin systems
[26–28], and there have been several reports of psychiatric
symptoms associated with the use of ginseng both in healthy
people and in patients previously affected by psychiatric
disorders (reviewed below).
In a psychological examination of 133 long-term ginseng
users, 18 cases of euphoria (after one-week use), 25 cases of
nervousness (after one-week use), 26 cases of sleeplessness
(after 3-week use), and 6 cases of depression (after 24-week
use) have been recorded, with high single doses (15 g) causing
feelings of depersonalization and confusion in 4 subjects
[29]. Anxiety and/or sleep disturbances were reported among
healthy volunteers taking ginseng monopreparations for 12
weeks (200mg/day) [30] or for 30 days (1000mg/day) [31]
in placebo-controlled trials [30, 31], as well as in healthy
individuals taking ginseng combination preparations [24].
In the World Health Organization (WHO) Collaborating
Centre for International Drug Monitoring Database and UK
Medicines Control Agency reports of adverse events, ginseng
monopreparations have been associated with cases of insom-
nia, nervousness, manic reaction, amnesia, somnolence, ano-
rexia, anxiety, emotional lability, hallucination, sleep disor-
der, confusion, depression, and abnormal thinking [24].
Some studies have also reported associations in the exac-
erbation or worsening of psychiatric symptoms with ginseng
use in patients affected by psychiatric disorders. Two case
reports by Gonzalez-Seijo et al. and Va´zquez and Agu¨era-
Ortiz suggest that ginsengmay have contributed to inducing a
manic episode in patients with previous diagnoses of affective
disorders [32, 33]. Gonzalez-Seijo et al. described the case of
a woman suffering from recurrent depressive episodes who
experienced a manic episode a few days after having self-
replaced her therapy (lithium carbonate 1200mg/day and
amitriptyline 75mg/day) with one tablet of ginseng every
day [32]. It is not known, however, if ginseng per se may
have induced the manic episode or, rather, the manic episode
was precipitated by amitriptyline or lithium withdrawal [32].
Va´zquez and Agu¨era-Ortiz reported the case of a 56-year-
old woman with previous major depressive disorder with
psychotic symptoms who presented a manic episode during
ginseng intake [33]; symptoms disappeared rapidly with low
doses of neuroleptics and benzodiazepines after ginseng
suppression [33]. However, Va´zquez and Agu¨era-Ortiz could
not clarify the effective contribution of the ginseng suppres-
sion to the amelioration of symptoms [33]. A third report
described that five inpatients with schizophrenia became
irritable, uncooperative, and overactive with disturbed sleep
after smoking ginseng-containing cigarettes and that, after
cessation of smoking these cigarettes, these behavioural
symptoms improved [34].
3.2. Ephedra sinica. Ephedra sinica (ma-huang) is an ever-
green shrub native to Central Asia, whose dried parts have
been used for thousands of years in the traditional Chinese
medicine for the treatment of various respiratory conditions
[35]. Its main biologically active component is the alkaloid
ephedrine, a sympathomimetic agent [36]. The chemical
structure of ephedrine is very similar to that of amphetamine;
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in fact, amphetamines have been originally synthesized as a
substitute for ephedrine [36].
In 1972, a Danish physician first noted unintentional
weight loss in a patient taking ephedrine-containing pills for
asthma [37]. Subsequently,ma-huang became one of themost
commonly used herbs for weight loss [38]. A meta-analysis
reported thatma-huang promotedmodest short-termweight
loss (approximately 0.6 kg/mo more than placebo), although
there are no data regarding long-term outcomes [39]. This
effect is said to be mainly due to a sympathomimetic stimula-
tion of thermogenesis in skeletal muscles [37, 40]. Ephedrine
can rapidly pass through the blood-brain barrier [35] and
can stimulate short-term release of dopamine and nore-
pinephrine, as well as long-term depletion of monoamine
[41]. Ma-huang use has been associated with several psychi-
atric adverse effects (reviewed below).
A meta-analysis of 50 trials on the use of ma-huang in
the treatment of obesity yielded estimates of 2.2- to 3.6-
fold increases in odds of developing psychiatric symptoms
including euphoria, neurotic behavior, agitation, depressed
mood, giddiness, irritability, and anxiety [39]. In a review of
1,820 previously unpublished Food andDrug Administration
(FDA) reports of adverse events concerning ma-huang, the
use of the herb was associated with 57 serious psychiatric
episodes [41]. Thirty-two (56.1%) of these cases included
reports of psychosis [41]. Other common adverse events (not
mutually exclusive) were severe depression (31.6%), mania
or severe agitation (26.3%), hallucinations, sleep disturbance,
and suicidal ideation (22.8% each) [41]. Of the 55 cases for
which gender was reported, 60% were women [41]. Most
patients (59.6%) had been using ephedra for more than 2
months [41]. Two-thirds of the 57 cases involved patients with
preexisting psychological/psychiatric conditions and/or the
use of other mood-altering medications or illicit substances
[41].
The first two cases of psychosis (one case of paranoid
psychosis and one case characterized by depression, para-
noid features, and vivid auditory hallucinations) caused by
ephedrine were described in 1968 by Herridge and a’Brook
[42]. Both patients reportedly used ephedrine to treat respi-
ratory diseases and had no previous mental illnesses [42]. A
1987 review of 20 cases of psychosis in patients mainly taking
ephedrine for respiratory diseases indicated the following:
(i) the typical clinical picture of ephedrine-related psychosis
was very similar to amphetamine-related psychosis, that is,
a paranoid psychosis with delusions and auditory halluci-
nations (less frequently visual hallucinations) in a setting of
clear consciousness; (ii) in the majority of cases, psychiatric
symptoms remitted following abstinence from ephedrine;
(iii) there was no personal or family history of psychosis in
18 of the cases; (iv) 80% of the patients had taken ephedrine
for more than 1 year; and (v) the average dose before the
psychotic episode was 510mg [36]. Among the described 20
patients, one patient suffered from “neurasthenia,” one from
“panic attacks,” three from “abnormal premorbid personal-
ity,” and two from substance abuse (morphine, amphetamine,
and LSD); all others had no history of previous psychiatric
disturbances [42]. Additional cases of ephedrine-induced
psychosis have more recently been described [43–46].
In relation to mood disorders, several published case
reports reported the association between ma-huang use and
manic-like symptoms, such as psychomotor agitation, pres-
sured speech, flight of ideas, suicidal ideation, irritability,
aggressive and disorganized behavior, and reduced need
for sleep [45–50]. Manic-like symptoms occurred both in
patients with no previous psychiatric illness and in patients
with a family history of bipolar disorder. These manic-like
symptoms occurred when ma-huang was being assumed at
the manufacturer recommended dosages, at doses exceeding
the recommended amounts, or after dose escalation (the
exact dosages were not reported) [45–50]. Following acute
manic episodes, symptom remission was typically achieved
with or without pharmacotherapy [45–50], although one
patient reportedly developed long-lasting residual distur-
bances such as boundary control and obtrusive, loud speech
[47]. Two case reports also detected the association between
ma-huang use and depressed mood [44, 45], with depressive
symptoms occurring after 1 year of use [44] or after the first
use [45] of the herb. Another case report described a woman
with severe obsessive-compulsive disorder who was effec-
tively treated with fluvoxamine and Eye Movement Desen-
sitization and Reprocessing (EMDR) treatments but relapsed
following the ingestion of a single capsule of an herbal prod-
uct containing ma-huang used to facilitate weight loss [51].
An additional relevant adverse psychiatric effect possibly
related to ma-huang use is the onset of ephedrine addic-
tion. Miller and Waite reported the case of a 20-year-old
male with no psychiatric comorbidity whose use of a dietary
supplement containing ma-huang progressed to substance
abuse and quite possibly substance dependence [52]. He
progressively escalated the assumed dose to more than four
times the recommended amount (one capsule, two times
per day), exhibiting symptoms of tolerance and withdrawal
[52]. According to the product label, each capsule purport-
edly contained 313mg of ephedra extract (8% concentra-
tion, 25mg of ephedrine group alkaloids) and 50mg of
anhydrous caffeine [52]. In a case series of seven patients
with amphetamine-like abuse or dependence, two showed
ephedrine abuse and three ephedrine dependence according
to the DSM-IV diagnostic criteria [53].The 2001 FDA reports
of adverse events found five patients (8.6%) that either
self-reported or were diagnosed as being addicted to ma-
huang products [41]. Finally, a study conducted on 64 female
weightlifters identified 36 ephedrine users, 7 of which (19%)
showed frank ephedrine dependence, including tolerance
and withdrawal symptoms, persistent use despite adverse
effects, andmultiple unsuccessful attempts to discontinue use
[54].
3.3. Paullinia cupana. Paullinia cupana (guarana) is a plant
native to the Amazon region and is especially common in
Brazil [55]. Guarana seeds contain a wide number of stimu-
lant and psychoactive substances, including twice the amount
of caffeine present in coffee beans and other xanthine alka-
loids such as theobromine and theophylline [55, 56]. The
plant is commonly used in soft drinks and energy drinks but
its stimulant properties have made it a frequent ingredient in
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weight-loss compounds, with some evidence supporting its
weight-loss effectiveness [47–49].
Due to the high caffeine content of its seeds, excessive
intake of guarana may cause symptoms of caffeine intoxica-
tion (e.g., nausea, palpitations, anxiety, excitement, insomnia,
and irritability) [23, 57, 58]. Baghkhani and Jafari reported the
case of a patient experiencing heart palpitations associated
with anxiety and irritability after using herbal supplements
containing guarana (with a daily dose of 400mg to 4 g) [59].
The World Health Organization-Adverse Drug Reactions
(WHO-ADR) database reported guarana to be associated
with cases of personality disorder, manic reaction, insomnia,
somnolence, asthenia, fatigue, anxiety, and impaired concen-
tration [23, 60]. Galduro´z and Carlini [61] and Boozer et
al. [62] conducted clinical trials aimed at assessing the effi-
cacy of herbal supplement containing guarana for cognitive
enhancement [61] or weight loss [62] reporting insomnia
among the adverse symptoms most frequently experienced
by participants.
3.4. Pausinystalia yohimbe. Pausinystalia yohimbe is a plant
native to Central Africa [63].The association between yohim-
bine, an alkaloid derived from the bark of the plant, and
weight loss has been consistently reported [23, 63–66]. For
example, Kucio et al. [63] documented that, compared to
placebo, yohimbine (5mg taken 4 times a day for 3 weeks)
combined with a low-energy diet significantly increased
the mean weight loss in obese patients. Yohimbine is an
alpha2-adrenoceptor antagonist that produces sympathetic
activation by increasing noradrenaline release and the firing
rate of neurons located in noradrenergic nuclei of the central
nervous system (CNS) [67, 68]. Consistently, increases in
anxiety symptoms are the most commonly reported adverse
psychiatric effects associated with yohimbine, both in healthy
people [69, 70] and in psychiatric patients (especially in those
with preexistent anxiety disorders) [71–76].
In healthy individuals, an intravenous dose of yohimbine
(0.15mg/kg up to a maximum dose of 10mg) produced a sig-
nificant increase in anxiety symptoms (e.g., mental and phys-
ical anxiety and irritability), along with an increase in systolic
and diastolic blood pressure, and hyperventilation [69]. A
significant decrease of cerebral blood flow, especially in the
cortical regions, following yohimbine administration has also
been observed [69]. Charney et al. reported that, compared
to placebo, an intravenous dose of yohimbine (0.4mg/kg) in
patients with panic disorder was associated with a significant
increase in anxiety ratings after 15 and 30 minutes [71]. A
trend towards a significant increase in anxiety levels was
also observed in healthy individuals after 15 minutes of
yohimbine administration [71]. It has been reported [72, 73]
that oral administration of yohimbine (20mg) can produce
a significant increase of subjective (i.e., nervousness and
frequent panic attacks) and objective (i.e., palpitations, hot
and cold flashes, tremors, etc.) anxiety symptoms in patients
with agoraphobia. Furthermore, Gurguis et al. reported that
the oral administration of yohimbine (20mg) induced panic
episodes in 6 of 11 patients diagnosed with agoraphobia
with panic attacks and significantly increased systolic blood
pressure, plasma norepinephrine, and cortisol levels [76].
The increase of anxiety symptoms after intravenous dose of
yohimbine (0.4mg/kg) has been also documented in combat
veterans with posttraumatic stress disorder (PTSD) [74, 75],
who concomitantly showed significant decreases in brain
metabolism after yohimbine administration compared to
healthy controls [75].
In addition to anxiety, yohimbine has also been associated
with other adverse psychiatric effects. Yohimbine has been
reported to induce addictive drug seeking behaviour [77],
objective and subjective withdrawal, and elevated craving in
heroin-dependent patients [78]. Scherr et al. [79] described
the case of a 21-year-old female patient who developed alter-
ations in alcohol and cocaine seeking behaviour and several
modifications in behaviour, including suicidal tendencies,
following the use of yohimbine for weight loss. It is reported
that, compared to placebo, oral administration of yohimbine
(0.4mg/kg [80] or up to 40mg [81]) can increase impulsivity
in healthy subjects [80, 81]. Finally, Price et al. [82] described
three cases of patients with bipolar depressionwho developed
manic symptoms after taking a 10mg dose of yohimbine.
The US National Institute of Health states that “people with
psychiatric conditions should not use Yohimbe” [83].
4. Interaction between
Weight-Loss-Related Herbal Products and
Psychiatric Medications
Herb-drug interactions have become an important issue in
drug safety and clinical practice, possibly resulting in drug
toxicities, reduced pharmacological effects, and adverse drug
reactions. In this section we review the available evidence of
interactions between HWLPs and psychiatric medications.
4.1. Panax ginseng. Two case reports suggest an interaction
between ginseng and phenelzine [84–86]. A 64-year-old
woman described symptoms of headache and tremulousness
when ginseng was added to her phenelzine therapy; three
years later, whilst still taking phenelzine, she experienced
similar symptoms upon ingesting ginseng capsules [85, 86]. A
43-year-old woman who had had a long-standing depressive
illness andwhosemedication included phenelzine 45mg/day,
triazolam 0.5mg/day, and lorazepam 4mg/day experienced
an improvement in her depression; this improvement esca-
lated into manic-like symptoms whilst taking a combination
of ginseng and bee pollen. When the ginseng preparation
was discontinued, she no longer experienced any therapeu-
tic benefit of the phenelzine [84]. An interaction between
ginseng, vitamin B complex, and sertraline resulting in a
reduction of therapeutic response has also been reported
[24]. Ginseng contains a mixture of saponin glycosides called
ginsenosides. It has been found that ginsenosides inhibit
cyclic AMP phosphodiesterase [87]; this may account partly
for ginseng interaction with monoamine oxidase inhibitors
(MAOIs) such as phenelzine, although an exact delineation
of the mechanism would require further study.
4.2. Ephedra sinica. Aswritten above, the predominant active
component of ma-huang, that is, ephedrine, is a sympath-
omimetic agent with a chemical structure very similar to that
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of amphetamine [36]. It acts directly and indirectly at alpha-
and beta-adrenergic receptors, potentially causing increased
blood pressure and heart rate, relaxation of bronchial and
gastrointestinal smoothmuscle, CNS stimulation, andmydri-
asis [88]. When ma-huang is administered in combination
with MAOIs, its sympathomimetic activity can reportedly
increase the risk of hypertensive crisis [89]. It is reported that
a 28-year-old woman taking phenelzine (60mg/day) devel-
oped encephalopathy, neuromuscular irritability, hypoten-
sion, tachycardia, rhabdomyolysis, and hyperthermia follow-
ing ingestion of a combination tablet containing ephedrine
(18.31mg), caffeine (30mg), and theophylline (100mg), 24
hours after abruptly discontinuing phenelzine treatment [89].
However, it is also possible that stopping the phenelzine
suddenly contributed to inducing the side effects.
4.3. Paullinia cupana. Guarana extracts have high content of
caffeine [55, 56], which is metabolized by CYP1A2 (a protein
of the cytochrome P450 family of isoenzymes responsible for
the biotransformation of several drugs) [58, 90]. When used
concomitantly, caffeine and certain psychiatric medications
(e.g., clozapine [91–94] and fluvoxamine [92]) can compete
for the same enzyme, resulting in potential increases in
medications’ drug levels and risks of toxic effects [91–94].
One study has also reported that abruptly ceasing the daily
consumption of caffeinemay result in a significant increase in
lithium blood levels [95]. However, no studies have reported
interactions between guarana and psychiatric medications so
far.
4.4. Pausinystalia yohimbe. Pharmacodynamic and pharma-
cokinetic interactions between yohimbine and certain tri-
cyclic antidepressants (i.e., clomipramine, desmethylclomi-
pramine, and imipramine) have been described [96–98].
It has been reported that yohimbine toxicity is poten-
tiated by tricyclic antidepressants and phenothiazines in
mice [99]. Lacomblez et al. [97] performed a double-blind,
crossover, placebo-controlled study in 12 depressed patients
with clomipramine-induced orthostatic hypotension report-
ing that low oral doses (4mg three times a day) of yohimbine
increased blood pressure, subsequently proposing yohimbine
as a possible drug-induced orthostatic hypotension corrector.
In addition, one preclinical [100] and one clinical study
[90] suggested that concomitant administration of yohim-
bine may lead to more rapid rates of psychiatric effects of
selective serotonin reuptake inhibitors (SSRIs) by shortening
the delay in obtaining tonic activation of the postsynaptic
5-HT1a receptors through its alpha2-antagonist activity. The
US National Institute of Health claimed that “people should
not combine Yohimbe with monoamine oxidase inhibitors as
effects may be additive. Yohimbe should be used with caution
when taken with medicines for high blood pressure, tricyclic
antidepressants, or phenothiazines” [83].
4.5. Plantago psyllium. Fibre supplements of Plantago
psyllium (psyllium) may contribute to a salutary lipid, glu-
cose, and insulin metabolism and are extensively used for
weight-loss purposes [101]. Two studies to date have reported
interactions between psyllium and psychiatric drugs:
Fong et al. recently found that psyllium supplements sig-
nificantly altered blood concentrations of carbamazepine
[102], while Perlman in 1990 reported that psyllium can
inhibit the absorption of lithium from the gastrointestinal
tract leading to reduced blood concentrations and clinical
effects of the drug [103].
4.6. Rhodiola rosea. Rhodiola rosea (Rhodiola) has a long his-
tory as a valuable medicinal plant having appeared in the
Materia Medica of a number of European countries [104].
As a dietary supplement, numerous preparations of Rhodiola
extracts are used worldwide as “adaptogen” substances [105].
Rhodiola use has been suggested to reduce food intake [47,
48] and to inhibit angiotensin converting enzyme (ACE),
resulting in a possible positive effect on metabolism [106].
Rhodiola canmodulate hypothalamic-pituitary-adrenal (HPA)
axis activity as well as that of several neurotransmitters
[104]. Maniscalco et al. recently reported the case of a 68-
year-old female patient with recurrent moderate depressive
disorder with somatic syndrome who developed vegeta-
tive syndrome, feelings of restlessness, and trembling since
she began ingesting Rhodiola supplements in addition to
paroxetine [107]. These symptoms may have been due to
serotonergic syndrome [107]; therefore, it is possible that
concomitant use of Rhodiola and selective SSRIs may lead
to an excess of serotonin in the CNS and/or in peripheral
nervous system with subsequent increased clinical risks.
4.7. Trigonella foenum-graecum. Seed extracts of Trigonella
foenum-graecum (fenugreek) have long been used as an
herbalmedicine for treatingmetabolic and nutritive dysfunc-
tions and have been shown to selectively reduce spontaneous
fat intake in overweight subjects [108]. Pharmacodynamic
interactions of fenugreek with MAOIs and SSRIs have been
described in vitro [109], although reliable human data are
lacking.
5. Conclusion
The consumption of HWLPs as the fastest and “healthiest”
way to lose weight is a relatively new and poorly studied phe-
nomenon. To the best of our knowledge, this is the first study
aimed at specifically reviewing the adverse psychiatric effects
associated with HWLPs. Results indicate that a range of
adverse psychiatric events could theoretically result from the
use of HWLPs.Though the evidence of psychiatric symptoms
associated with HWLPs may collectively look impressive,
the information provided in the reviewed studies is often
insufficient for making reliable inferences about causality;
therefore, in some cases it may be unnecessarily alarmist
to accept a cause-effect relationship between HWLPs and
psychiatric symptoms.
In addition to the reviewed evidence (i.e., the effects of
HWLPs per se on psychiatric symptoms and the interactions
of HWLPs with psychiatric drugs), there are four further
reasons of possible concern in relation to the potential
psychiatric adverse effects of certain HWLPs.
(i) The HWLPs may contain adulterants with the poten-
tial to cause neurotoxicity or adverse interactions. Herbal
6 BioMed Research International
products, in fact, undergo reduced quality control and safety
testing in comparison to medications [18]. For example,
adulterants that have been identified in HWLPs include
sibutramine [110], fenfluramine [111], or thyroid hormones
[112, 113], which are molecules with well-known potential
deleterious effects onCNS,mental status, and behaviour [114–
116]. (ii) Individuals are using increasingly large amounts of
herbal products as “weight-loss adjuvant interventions” in
addition to the standard HWLPs. For example, Valeriana
officinalis (valerian), Passiflora incarnata (purple passion-
flower), Melissa officinalis (lemon balm), and Hypericum
perforatum (St. John’s wort) have long been used to improve
sleep, anxiety, or mood disturbances [117–119]; these herbal
products can interact with a range of neurotransmitter sys-
tems, having the potential to induce adverse psychiatric and
cognitive effects [112, 113, 118, 120–124] and to interact with
psychiatric medications [118, 125–127]. Even though extracts
of these herbs have never been shown to improve obesity
or metabolism, they are often sold on the Internet with the
purpose of calming stress-induced hunger and eating behav-
iours related to nervousness [19, 128–130]. People, in fact, are
becoming increasingly aware of the link betweenmood, poor
sleep quality, and obesity [19, 128, 130, 131]. In an attempt
to address mood and sleep disturbances, consumers may
use products containing extracts of these plants, considering
this intervention to be a relevant part of their weight-loss
program [19, 128–130] and subsequently increasing their
risk of adverse psychiatric effects. (iii) A range of HWLPs
can interact with enzymes involved in psychiatric drug
metabolism [132], having the potential to interfere with phar-
macokinetic mechanisms. (iv) Finally, obesity is associated
with significant increases in lifetime diagnosis of mood and
anxiety disorders [133, 134]. It is possible that obesity per
se may lead to higher vulnerability to the development of
psychiatric disorders [133], meaning that obese individuals
may represent a psychiatrically at-risk population and the use
of HWLPs with potential adverse psychiatric effects among
them may be of particular concern.
In conclusion, adverse psychiatric events and interac-
tions with psychiatric drugs are reported for a number of
herbal products commonly used for reducing body weight.
Physicians, psychiatrists, and other health and mental health
professionals should remind patients that (i) diet, exercise,
and healthy lifestyle are the safest and most effective weight-
loss strategies and (ii) the HWLPs, though potentially effec-
tive for weight loss, may have a heterogeneous nature and
may be associated with psychiatric risks. It is also true that
certain HWLPs may exert beneficial effects on CNS and on
certain psychiatric conditions [135], but this analysis was not
included as a part of the objective of the present review.
Future studies should include safety mental health measures
in relation to this growing pattern of substance use.
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